RT Journal Article
SR Electronic
T1 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P5093
VO 42
IS Suppl 57
A1 Caroline Becker
A1 Enric Carcereny Costa
A1 Felipe Andreo Garcia
A1 Eva Castellá
A1 Mariona Lletjós Sanuy
A1 Teresa Morán
A1 Erika Mijangos Basterra
A1 José Sanz Santos
A1 Carmen Centeno Clemente
A1 Juan Ruiz Manzano
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P5093.abstract
AB IntroductionRecent progresses in targeted therapy of lung cancer have achieved remarkable results in advanced disease. It was generally considered that cytological samples were less likely to be suitable for molecular studies. To assess the validity of using cytological specimens for conducting molecular tests, we performed this retrospective study of cytology samples from Non-Small-Cell lung cancer (NSCLC) patients to determine the presence of EGFR, KRAS and/or ALK mutations.Material and methodsFrom 2007 to 2012,233 samples of patients with NSCLC collected at the Deparment of Pathology of our institution were analyzed for the presence of EGFR, KRAS and/or ALK mutations. Biological fluids, bronchoscopy samples, CT guided transthoracic and endobronchial ultrasound guided fine needle aspiration were used. Samples were processed as cell blocks or membrane extensions. Subsequently, tumor cells were selected by micro dissection and DNA sequencing was performed at our Molecular Biology Laboratory.ResultsEGFR mutations were analyzed in 233 samples,the mutations were found in 16/233 (6.8%) and their determination performance was 90.1% (not assessable in 13 samples,insufficient tissue in 6, no tumor in 4). KRAS mutations were tested in 49 samples with a mutation frequency of 14.3 % (7/49) and a performance of 81.63% (not assessable in 5,insufficient tumor cells in 3, no tumor 1) ALK mutations were analyzed in 8 samples with a performance of 62.5% (insufficient samples 2, pending 1).ConclusionsThese results show that the analysis of EGFR, KRAS and ALK mutations in several cytological samples is feasible with a high performance.Therefore it should be an option to consider in clinical practice.